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We deeply appreciate the great contributions of many physicians in the registry of esophageal cancer cases. The Comprehensive Registry of Esophageal Cancer in Japan, 2012, was published here, despite some delay. The registry complies with the Act for the Protection of Personal Information. The encryption with a HASH function is used for anonymity in an unlinkable fashion.

We briefly summarized the Comprehensive Registry of Esophageal Cancer in Japan, 2012. Japanese Classification of Esophageal Cancer 10th \[[@CR1]\] and UICC TNM Classification 7th \[[@CR2]\] were used for cancer staging according to the subjected year. A total of 8003 cases were registered from 316 institutions in Japan. Tumor locations were cervical: 4.6%, upper thoracic: 12.8%, middle thoracic: 47.9%, lower thoracic: 26.1% and EG junction: 7.6%. Superficial carcinomas (Tis, T1a, T1b) were 38.2%. As for the histologic type of biopsy specimens, squamous cell carcinoma and adenocarcinoma accounted for 89.5% and 6.0%, respectively. Regarding clinical results, the 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, or esophagectomy were 84.4, 32.4, 24.9, and 55.6%, respectively. The endoscopic submucosal dissection accounted for 84.9% of endoscopic resection. Esophagectomy was performed in 4722 cases. Concerning the approach used for esophagectomy, 36.0% of the cases were treated thoracoscopically. The operative mortality (within 30 days after surgery) was 0.52% and the hospital mortality was 2.35%. The 5-year survival rate of patients with pStage IV in UICC classification (including patients with supraclavicular node metastasis) was better than that of patients with pStage IVb in JES classification (not including patients with supraclavicular node metastasis).

We hope that this Comprehensive Registry of Esophageal Cancer in Japan for 2012 will help to improve all aspects of the diagnosis and treatment of esophageal cancer in Japan.
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Institution-registered cases in 2012

InstitutionAgeo Central General HospitalAichi Cancer CenterAichi Medical University HospitalAizawa HospitalAkaishi HospitalAkita Kouseiren Hiraga HospitalAkita University HospitalAomori City HospitalArao Municipal HospitalAsahikawa Medical College HospitalCancer Institute Hospital of JFCRChiba Cancer CenterChiba Medical CenterChiba University HospitalChibaken Saiseikai Narashino HospitalChigasaki Municipal HospitalDokkyo Medical University HospitalDokkyo Medical University Saitama Medical CenterEhime University HospitalEiju General HospitalFoundation for Detection of Early Gastric CarcinomaFuchu HospitalFujioka General HospitalFujisawa Shounandai HospitalFujita Health University HospitalFukui Prefectural HospitalFukui University HospitalFukui-ken Saiseikai HospitalFukuoka Dental College and Dental HospitalFukuoka Saiseikai General HospitalFukuoka University Chikushi HospitalFukuoka University HospitalFukuoka Wajiro HospitalFukushima Medical University HospitalFukuyama City HospitalFussa HospitalGifu Prefectural General Medical CenterGifu University HospitalGunma Central General HospitalGunma Prefectural Cancer CenterGunma University HospitalGunmaken Saiseikai Maebashi HospitalHachinohe City HospitalHakodate Goryokaku HospitalHakodate National HospitalHamamatsu University School of Medicine, University HospitalHeartlife HospitalHigashiosaka City Medical CenterHino Memorial HospitalHino Municipal HospitalHiratsuka City HospitalHiratsuka Kyosai HospitalHirosaki University HospitalHiroshima City Asa HospitalHiroshima City Hiroshima Citizens HospitalHiroshima Red Cross Hospital & Atomic-bomb Survivors HospitalHiroshima University HospitalHitachi General HospitalHokkaido University HospitalHyogo Cancer CenterHyogo Prefectural Nishinomiya HospitalIbaraki Prefectural Central HospitalIizuka HospitalImazu Surgical ClinicInazawa City HospitalInternational University of Health and Welfare HospitalInternational Goodwill HospitalInternational University of Health and Welfare Mita HospitalIsehara Kyodo HospitalIshikawa Prefectural Central HospitalIwate Medical University HospitalIwate Prefectural Central HospitalIwate Prefectural Chubu HospitalIwate Prefectural Isawa HospitalJapanese Red Cross Fukui HospitalJapanese Red Cross Ishinomaki HospitalJapanese Red Cross Kyoto Daini HospitalJapanese Red Cross Nagaoka HospitalJapanese Red Cross Okayama HospitalJapanese Red Cross Society Kyoto Daiichi HospitalJapanese Red Cross Tottori HospitalJCHO Kurume General HospitalJCHO Kyushu HospitalJCHO Miyazaki Konan HospitalJCHO Osaka HospitalJCHO Saitama Medical CenterJCHO Tokuyama Central HospitalJCHO Yokohama Chuo HospitalJichi Medical University HospitalJichi Medical University Saitama Medical CenterJuntendo University HospitalJuntendo University Shizuoka HospitalJunwakai Memorial HospitalKagawa Prefectural Central HospitalKagawa Rosai HospitalKagawa University HospitalKagoshima Kenritsu Satsunan HospitalKagoshima University HospitalKaizuka City HospitalKameda General HospitalKanagawa Cancer CenterKanazawa University HospitalKansai Medical University HospitalKansai Medical University Medical CenterKansai Rosai HospitalKasamatsu HospitalKashiwa Kousei General HospitalKawakita General HospitalKawasaki Medical School HospitalKawasaki Medical School Kawasaki HospitalKawasaki Municipal Ida HospitalKeio University HospitalKeiyukai Sapporo HospitalKikuna Memorial HospitalKin-ikyo Chuo HospitalKinki Central HospitalKinki University HospitalKiryu Kosei General HospitalKishiwada City HospitalKitaakita Municipal HospitalKitakyushu Municipal Medical CenterKitano HospitalKitasato Institute HospitalKitasato University HospitalKobe City Medical Center General HospitalKobe City Nishi-Kobe Medical CenterKobe University HospitalKochi Health Sciences CenterKochi University HospitalKokura Memorial HospitalKumagaya General HospitalKumamoto City HospitalKumamoto University HospitalKurashiki Central HospitalKurume University HospitalKusatsu General HospitalKyorin University HospitalKyoto University HospitalKyushu Central Hospital of the Mutual Aid Association of Public School TeachersKyushu Medical CenterKyushu University Beppu HospitalKyushu University HospitalMachida Municipal HospitalMatsuda HospitalMatsudo City HospitalMatsushita Memorial HospitalMatsuyama Red Cross HospitalMie University HospitalMinamiosaka HospitalMinamiyamato HospitalMino City HospitalMito Red Cross HospitalMitsui Memorial HospitalMoriguchi Keijinkai HospitalMurakami General HospitalMusashino Red Cross HospitalNagahama City HospitalNagano Red Cross HospitalNagaoka Chuo General HospitalNagasaki University HospitalNagoya City East Medical CenterNagoya City University HospitalNagoya City West Medical CenterNagoya Daiichi Red Cross HospitalNagoya University HospitalNanpuh HospitalNara City HospitalNara Medical University HospitalNational Cancer Center HospitalNational Cancer Center Hospital EastNational Defense Medical College HospitalNational Institute of Radiological Sciences HospitalNerima Hikarigaoka HospitalNHO Beppu Medical CenterNHO Chiba Medical CenterNHO Chiba-East-HospitalNHO Fukuoka-higashi Medical CenterNHO Himeji Medical CenterNHO Hokkaido Cancer CenterNHO Kanmon Medical CenterNHO Kure Medical CenterNHO Kyoto Medical CenterNHO Kyushu Cancer CenterNHO Matsumoto Medical CenterNHO Nagasaki Medical Center.NHO Nagoya Medical CenterNHO Okayama Medical CenterNHO Osaka National HospitalNHO Tokyo Medical CenterNihonkai General HospitalNiigata Cancer Center HospitalNiigata City General HospitalNiigata Prefectural Shibata HospitalNiigata University Medical and Dental HospitalNikko Memorial HospitalNippon Medical School Chiba Hokusoh HospitalNippon Medical School HospitalNippon Medical School Musashi Kosugi HospitalNippon Medical School Tama Nagayama HospitalNishinomiya Municipal Central HospitalNTT Medical Center TokyoNTT WEST Osaka HospitalNumazu City HospitalObihiro Kousei HospitalOgachi Central HospitalOgaki Municipal HospitalOhta Nishinouchi HospitalOita Red Cross HospitalOita University HospitalOkayama Saiseikai General HospitalOkayama University HospitalOmuta Tenryo HospitalOsaka City General HospitalOsaka City University HospitalOsaka Ekisaikai HospitalOsaka General Medical CenterOsaka International Cancer InstituteOsaka Medical College HospitalOsaka Police HospitalOsaka Red Cross HospitalOsaka University HospitalOtsu City HospitalRinku General Medical CenterRyukyu University HospitalSaga University HospitalSaga-ken Medical Center KoseikanSaiseikai Fukushima General HospitalSaiseikai Kyoto HospitalSaiseikai Utsunomiya HospitalSaiseikai Yahata General HospitalSaiseikai Yokohamashi Tobu HospitalSaitama Cancer CenterSaitama City HospitalSaitama Medical University HospitalSaitama Medical University International Medical CenterSaitama Medical University Saitama Medical CenterSakai City Medical CenterSaku Central HospitalSanin Rosai HospitalSendai City HospitalSendai Medical CenterShiga General HospitalShiga University of Medical Science HospitalShikoku Cancer CenterShimane University HospitalShimizu Welfare HospitalShinko HospitalShizuoka Cancer CenterShizuoka City Shizuoka HospitalShizuoka General HospitalShowa University HospitalShowa University Koto-Toyosu HospitalSonoda Daiichi HospitalSouthern Tohoku General HospitalSt. Luke's International HospitalSt. Marianna University School of Medical HospitalSteel Memorial Hirohata HospitalSugita Genpaku Memorial Obama Municipal HospitalSuita Municipal HospitalTachikawa HospitalTakasago Municipal HospitalTeikyo University Chiba Medical CenterTeikyo University HospitalTeine Keijinkai HospitalTenri HospitalThe Jikei University Daisan HospitalThe Jikei University HospitalTochigi Cancer CenterToho University Ohashi Medical CenterToho University Omori Medical CenterToho University Sakura Medical CenterTohoku University HospitalTokai University Hachioji HospitalTokai University HospitalTokai University Tokyo HospitalTokushima Red Cross HospitalTokushima University HospitalTokyo Dental College Ichikawa General HospitalTokyo Medical and Dental University HospitalTokyo Medical University Hachioji Medical CenterTokyo Medical University HospitalTokyo Medical University Ibaraki Medical CenterTokyo Metropolitan Cancer and Infectious Diseases Center Komagome HospitalTokyo Metropolitan Tama Medical CenterTokyo Saiseikai Central HospitalTokyo University HospitalTokyo Women's Medical University HospitalTokyo Women's Medical University Medical Center EastTokyo Women's Medical University Yachiyo Medical CenterTonan HospitalToranomon HospitalToshima HospitalTottori Prefectural Central HospitalTottori University HospitalToyama Prefectural Central HospitalToyama University HospitalToyonaka Municipal HospitalTsuchiura Kyodo HospitalTsukuba University HospitalTsuruoka Municipal Shonai HospitalUniversity Hospital, Kyoto Prefectural University of MedicineUniversity of Miyazaki HospitalUrasoe General HospitalWakayama Medical University HospitalYamagata Prefectural Central HospitalYamagata Prefectural Shinjo HospitalYamagata University HospitalYamaguchi University HospitalYamaguchi-ken Saiseikai Shimonoseki General HospitalYamanashi Prefectural Central HospitalYamanashi University HospitalYao Municipal HospitalYokohama City Municipal HospitalYokohama City University Medical CenterYokohama Rosai HospitalYuri Kumiai General Hospital(Total 316 institutions)
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Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}.Table 1Age and genderAgeMaleFemaleCases (%)≤ 29314 (0.0%)30-39161430 (0.4%)40-4916358221 (2.8%)50-5910281881216 (15.2%)60-6928144533267 (40.8%)70-7922743712645 (33.1%)80-89476118594 (7.4%)90≤18826 (0.3%)Total679212118003Table 2Primary treatmentTreatmentsCases (%)Surgery4798 (60.0%) Esophagectomy4722 (59.0%) Palliative surgery76 (1.0%)Chemotherapy/radiotherapy1794 (22.4%)Endoscopic treatment1407 (17.6%)Total7999Table 3Tumor locationLocation of tumorEndoscopic treatment (%)SurgeryChemotherapy and/or radiotherapy (%)Total (%)Esophagectomy (%)Palliative surgery (%)Cervical41 (2.9%)152 (3.2%)3 (3.9%)174 (9.7%)370 (4.6%)Upper thoracic122 (8.7%)581 (12.3%)18 (23.7%)302 (16.8%)1023 (12.8%)Middle thoracic819 (58.2%)2151 (45.6%)37 (48.7%)825 (46.0%)3832 (47.9%)Lower thoracic335 (23.8%)1344 (28.5%)14 (18.4%)392 (21.9%)2085 (26.1%)EG58 (4.1%)356 (7.5%)2 (2.6%)39 (2.2%)455 (5.7%)E = G14 (1.0%)56 (1.2%)1 (1.3%)10 (0.6%)81 (1.0%)GE4 (0.3%)59 (1.2%)1 (1.3%)7 (0.4%)71 (0.9%)Unknown14 (1.0%)23 (0.5%)45 (2.5%)82 (1.0%)Total140747227617947999*E* esophageal, *G* gastricTable 4Histologic types of biopsy specimensHistologic typesCases (%)Squamous cell carcinoma7162 (89.5%) Squamous cell carcinoma5130 (64.1%) Well differentiated440 (5.5%) Moderately differentiated1177 (14.7%) Poorly differentiated415 (5.2%)Adenocarcinoma358 (4.5%)Barrett's adenocarcinoma119 (1.5%)Adenosquamous carcinoma15 (0.2%)Mucoepidermoid carcinoma6 (0.1%)Basaloid carcinoma41 (0.5%)Neuroendocrine cell tumor24 (0.3%)Undifferentiated carcinoma12 (0.2%)Sarcoma79 (1.0%)Malignant melanoma1 (0.0%)Carcinosarcoma19 (0.2%)GIST14 (0.2%)Other tumors2 (0.0%)Unknown147 (1.8%)Total7999Table 5Depth of tumor invasion, cT (UICC TNM 7th)cTCases (%)cTX100 (1.3%)cT014 (0.2%)cTis216 (2.7%)cT1a1264 (15.8%)cT1b1575 (19.7%)cT21004 (12.6%)cT32843 (35.5%)cT4a395 (4.9%)cT4b538 (6.7%)Unknown50 (0.6%)Total7999Table 6Lymph node metastasis, cN (UICC TNM 7th)cNCases (%)cNX170 (2.1%)cN03796 (47.5%)cN12020 (25.3%)cN21335 (16.7%)cN3519 (6.5%)Unknown159 (2.0%)Total7999Table 7Distant metastasis, cM (UICC TNM 7th)cMCases (%)cM07214 (90.2%)cM1740 (9.3%)Unknown45 (0.6%)Total7999Table 8Clinical stage (UICC TNM 7th)Clinical StageEndoscopic treatment(%)SurgeryChemotherapy and/or radiotherapy (%)Total (%)Esophagectomy (%)Palliative surgery (%)Stage 0254 (18.1%)104 (2.2%)2 (2.6%)54 (3.0%)414 (5.2%)Stage IA981 (69.7%)1117 (23.7%)1 (1.3%)201 (11.2%)2300 (28.8%)Stage IB6 (0.4%)393 (8.3%)50 (2.8%)449 (5.6%)Stage IIA5 (0.4%)499 (10.6%)6 (7.9%)79 (4.4%)589 (7.4%)Stage IIB3 (0.2%)458 (9.7%)88 (4.9%)549 (6.9%)Stage IIIA9 (0.6%)951 (20.1%)14 (18.4%)210 (11.7%)1184 (14.8%)Stage IIIB10 (0.7%)510 (10.8%)6 (7.9%)117 (6.5%)643 (8.0%)Stage IIIC20 (1.4%)384 (8.1%)26 (34.2%)418 (23.3%)848 (10.6%)Stage IV36 (2.6%)183 (3.9%)16 (21.1%)505 (28.1%)740 (9.3%)Unknown83 (5.9%)123 (2.6%)5 (6.6%)72 (4.0%)283 (3.5%)Total140747227617947999
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Tables [9](#Tab9){ref-type="table"}, [10](#Tab10){ref-type="table"}, [11](#Tab11){ref-type="table"} and Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}.Table 9Details of endoscopic treatment for curative intentTreatment detailsCases (%)EMR185 (14.2%)EMR + YAG laser6 (0.5%)EMR + MCT/RFA1 (0.1%)ESD1064 (81.9%)ESD + EMR2 (0.2%)ESD + PDT8 (0.6%)ESD + YAG laser8 (0.6%)PDT3 (0.2%)YAG laser22 (1.7%)Total1299*EMR* endoscopic mucosal resection, *PDT* photodynamic therapy, *YAG* yttrium aluminum garnet, *MCT* microwave coagulation therapy, *ESD* endoscopic submucosal dissectionTable 10Complications of EMR/ESDComplications of EMR/ESDCases (%)None1206 (94.7%)Perforation20 (1.6%)Bleeding1 (0.1%)Stenosis35 (2.7%)Others5 (0.4%)Unknown7 (0.5%)Total1274Table 11Pathological depth of tumor invasion of EMR/ESD specimensPathological depth of tumor invasionCases (%)pTX6 (0.5%)pT010 (0.8%)pTis234 (18.4%)pT1a873 (68.5%)pT1b140 (11.0%)pT22 (0.2%)Unknown9 (0.7%)Total1274Fig. 1Survival of patients treated with EMR/ESDFig. 2Survival of patients treated with EMR/ESD according to the pathological depth of tumor invasion, pT (UICC TNM 7th)Fig. 3Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion
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Tables [12](#Tab12){ref-type="table"}, [13](#Tab13){ref-type="table"} and Figs. [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}.Table 12Dose of irradiation (non-surgically treated cases)Dose of irradiation (Gy)DefinitivePalliative (%)Recurrence (%)Others (%)Unknown (%)Total (%)Radiation alone (%)Chemoradiotherapy (%)− 297 (3.2%)14 (1.5%)14 (4.5%)1 (3.3%)36 (2.4%)30--393 (1.4%)13 (1.4%)46 (14.7%)1 (20.0%)5 (16.7%)1 (2.5%)69 (4.6%)40--494 (1.9%)36 (4.0%)63 (20.1%)1 (20.0%)7 (23.3%)1 (2.5%)112 (7.4%)50--5935 (16.2%)192 (21.2%)76 (24.3%)8 (26.7%)10 (25.0%)321 (21.3%)60--69127 (58.8%)546 (60.4%)103 (32.9%)3 (60.0%)7 (23.3%)27 (67.5%)813 (53.9%)70-7 (3.2%)30 (3.3%)4 (1.3%)(0.0%)41 (2.2%)Unknown33 (15.3%)73 (8.1%)7 (2.2%)2 (6.7%)1 (2.5%)116 (7.7%)Total216904313530401508Median (min--max)60.0 (2.0--139.0)60.0 (8.0--104.4)50.0 (2.0--126.0)60.0 (30.0--63.0)50.0 (4.5--63.0)60.0 (30.0--66.0)60.0 (2.0--139.0)Table 13Dose of irradiation (surgically treated cases)Dose of irradiation (Gy)Preoperative irradiation (%)Postoperative irradiation (%)− 293 (1.0%)1 (1.8%)30--3986 (28.6%)3 (5.4%)40--49166 (55.1%)9 (16.1%)50--5910 (3.3%)17 (30.4%)60--6923 (7.6%)23 (41.1%)70--Unknown13 (4.3%)3 (5.4%)Total30156Median (min--max)40.0 (3.0--66.6)50.5 (16.0--66.0)Fig. 4Survival of patients treated with chemotherapy and/or radiotherapyFig. 5Survival of patients treated with definitive chemoradiotherapy according to clinical stage (UICC TNM 7th)Fig. 6Survival of patients treated with radiotherapy alone according to clinical stage (UICC TNM 7th)

IV. Results in patients who underwent esophagectomy in 2012 {#Sec7}
-----------------------------------------------------------

Tables [14](#Tab14){ref-type="table"},[15](#Tab15){ref-type="table"},[16](#Tab16){ref-type="table"},[17](#Tab17){ref-type="table"},[18](#Tab18){ref-type="table"},[19](#Tab19){ref-type="table"},[20](#Tab20){ref-type="table"},[21](#Tab21){ref-type="table"},[22](#Tab22){ref-type="table"}[23](#Tab17){ref-type="table"},[24](#Tab17){ref-type="table"},[25](#Tab17){ref-type="table"},[26](#Tab17){ref-type="table"},[27](#Tab17){ref-type="table"}, and Figs. [7](#Fig7){ref-type="fig"}, [8](#Fig8){ref-type="fig"}, [9](#Fig9){ref-type="fig"}, [10](#Fig10){ref-type="fig"}, [11](#Fig11){ref-type="fig"}, [12](#Fig12){ref-type="fig"}, [13](#Fig13){ref-type="fig"}, [14](#Fig14){ref-type="fig"}, [15](#Fig15){ref-type="fig"}.Table 14Treatment modalities of esophagectomyTreatmentsCases (%)Esophagectomy1792 (38.0%)Esophagectomy + endoscopic treatment123 (2.6%)Esophagectomy + chemoradiotherapy806 (17.1%) Concurrent chemoradiotherapy557 (11.8%) Other249 (5.3%)Esophagectomy + chemoradiotherapy + endoscopic treatment24 (0.5%)Esophagectomy + chemoradiotherapy + other treatment1 (0.0%)Esophagectomy + radiotherapy67 (1.4%) Preoperative15 (0.3%) Postoperative23 (0.5%) Recurrence4 (0.1%) Other25 (0.5%)Esophagectomy + chemotherapy1886 (39.9%)Preoperative1473 (31.2%)Postoperative253 (5.4%)Recurrence52 (1.1%)Other108 (2.3%)Esophagectomy + chemotherapy + endoscopic treatment21 (0.4%)Esophagectomy + chemotherapy + other treatment1 (0.0%)Esophagectomy + other treatment1 (0.0%)Total4722Table 15Tumor locationLocationsCases (%)Cervical152 (3.2%)Upper thoracic581 (12.3%)Middle thoracic2151 (45.6%)Lower thoracic1344 (28.5%)*E* \> *G*356 (7.5%)*E* = *G*56 (1.2%)*G* \> *E*59 (1.2%)Unknown23 (0.5%)Total lesions4722Table 16Approaches to tumor resectionApproachesCases (%)Cervical approach83 (1.8%)Right thoracic4070 (86.2%)Left thoracic81 (1.7%)Left thoracoabdominal80 (1.7%)Abdominal173 (3.7%)Transhiatal thoracic esophagectomy59 (1.2%)Transhiatal lower esophagectomy115 (2.4%)Sternotomy9 (0.2%)Others25 (0.5%)Unknown27 (0.6%)Total4722Thoracic includes thoracotomy and thoracoscopicAbdominal includes laparotomy and laparoscopicTable 17Video-assisted surgeryVideo-assisted surgeryCases (%)None2623 (55.5%)Thoracoscopy983 (20.8%)Thoracoscopy + laparoscopy712 (15.1%)Thoracoscopy + laparoscopy + mediastinoscopy3 (0.1%)Thoracoscopy + laparoscopy + other1 (0.0%)Thoracoscopy + mediastinoscopy3 (0.1%)Thoracoscopy + other2 (0.0%)Laparoscopy218 (4.6%)Laparoscopy + mediastinoscopy11 (0.2%)Laparoscopy + mediastinoscopy + other13 (0.3%)Mediastinoscopy41 (0.9%)Others107 (2.3%)Unknown5 (0.1%)Total4722Table 18Fields of lymph node dissection according to the location of the tumorField of lymphadenectomyCervicalUpper thoracicMiddle thoracicLower thoracic*E* \> *GE* = *GG* \> *E*UnknownTotalNone19 (12.5%)27 (4.6%)81 (3.8%)39 (2.9%)17 (4.8%)3 (5.4%)11 (4.3%)188 (4.0%)C40 (26.3%)8 (1.4%)8 (0.4%)5 (0.4%)(0.0%)61 (1.3%)C + UM16 (10.5%)3 (0.5%)3 (0.1%)2 (0.1%)1 (1.8%)126 (0.6%)C + UM + MLM11 (7.2%)25 (4.3%)43 (2.0%)18 (1.3%)1 (0.3%)98 (2.1%)C + UM + MLM + A45 (29.6%)369 (63.5%)1103 (51.3%)506 (37.6%)39 (11.0%)3 (5.4%)1 (1.7%)6 (26.1%)2072 (43.9%)C + UM + MLM + A + OT1 (0.1%)1 (0.0%)C + UM + A3 (2.0%)5 (0.9%)1 (0.0%)2 (0.1%)11 (0.2%)C + MLM1(0.0%)1 (0.1%)2 (0.0%)C + MLM + A4 (0.3%)7 (0.3%)5 (0.4%)1 (0.3%)17 (0.4%)C + A2 (1.3%)4 (0.2%)1 (0.1%)7 (0.1%)UM5 (0.2%)2 (0.1%)3 (0.8%)10 (0.2%)UM + MLM1 (0.7%)11 (1.9%)33 (1.5%)14 (1.0%)4 (1.1%)2 (8.7%)65(1.4%)UM + MLM + A10 (6.6%)110 (18.9%)768 (35.7%)595 (44.3%)115 (32.3%)11 (19.6%)7 (11.9%)8 (34.8%)1624 (34.4%)UM + MLM + A + OT1 (0.1%)1 (0.0%)UM + A7 (0.3%)3 (0.2%)1 (0.3%)11 (0.2%)MLM1 (0.2%)9 (0.4%)7 (0.5%)4 (1.1%)21 (0.4%)MLM + A8 (1.4%)45 (2.1%)105 (7.8%)129 (36.2%)26 (46.4%)27 (45.8%)2 (8.7%)342 (7.2%)A1 (0.7%)3 (0.5%)21 (1.0%)29 (2.2%)40 (11.2%)9 (16.1%)23 (39.0%)1 (4.3%)127 (2.7%)A + OT1 (0.1%)1 (0.0%)Unknown4 (2.6%)6 (1.0%)11 (0.5%)9 (0.7%)2 (0.6%)3 (5.4%)2 (8.7%)37 (0.8%)Total15258121511344356564722*C* bilateral cervical nodes, *UM* upper mediastinal nodes, *MLM* middle-lower mediastinal nodes, *A* abdominal nodesTable 19Reconstruction routeRouteCases (%)None66 (1.4%)Subcutaneous414 (8.8%)Retrosternal1799 (38.1%)Posterior mediastinal519 (11.0%)Intrathoracic1794 (38.0%)Cervical46 (1.0%)Others49 (1.0%)Unknown35 (0.7%)Total4722Table 20Organs used for reconstructionOrgans used for reconstructionCases (%)None62 (1.3%)Whole stomach49 (1.0%)Gastric tube4057 (85.0%)Jejunum286 (6.0%)Free jejunum94 (2.0%)Colon157 (3.3%)Free colon12 (0.3%)Others24 (0.5%)Unknown33 (0.7%)Total organs4774Total cases4722Table 21Histological classificationHistological classificationCases (%)Squamous cell carcinoma3990 (84.5%) Squamous cell carcinoma973 (20.6%) Well differentiated713 (15.1%) Moderately differentiated1788 (37.9%) Poorly differentiated516 (10.9%)Adenocarcinoma239 (5.1%)Barrett's adenocarcinoma109 (2.3%)Adenosquamous carcinoma30 (0.6%)Mucoepidermoid carcinoma5 (0.1%)Adenoid cystic carcinoma3 (0.1%)Basaloid carcinoma81 (1.7%)Neuroendocrine cell tumor21 (0.4%)Undifferentiated carcinoma12 (0.3%)Other carcinoma6 (0.1%)Carcinosarcoma36 (0.8%)Malignant melanoma11 (0.2%)GIST1 (0.0%)Other46 (1.0%)Unknown132 (2.8%)Total4722Table 22Pathological depth of tumor invasion, pT (JES 10th)Pathological depth of tumor invasionCases (%)pTX71 (1.5%)pT0156 (3.3%)pTis33 (0.7%)pT1a503 (10.7%)pT1b1256 (26.6%)pT2570 (12.1%)pT31824 (38.6%)pT420 (0.4%)pT4a147 (3.1%)pT4b103 (2.2%)Unknown39 (0.8%)Total4722Fig. 7Survival of patients who underwent esophagectomyFig. 8Survival of patients who underwent esophagectomy according to clinical stage (JES 10th)Fig. 9Survival of patients who underwent esophagectomy according to clinical stage (UICC 7th)Fig. 10Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th)Fig. 11Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (JES 10th)Fig. 12Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (UICC 7th)Fig. 13Survival of patients who underwent esophagectomy according to pathological stage (JES 10th)Fig. 14Survival of patients who underwent esophagectomy according to pathological stage (UICC TNM 7th)Fig. 15Survival of patients who underwent esophagectomy according to residual tumor (R)Table 23Pathological grading of lymph node metastasis, pN (JES 10th)Lymph node metastasisCases (%)pN02237 (47.4%)pN1626 (13.3%)pN21172 (24.8%)pN3393 (8.3%)pN4226 (4.8%)Unknown68 (1.4%)Total4722Table 24Pathological findings of lymph node metastasis, pN (UICC 7th)Lymph node metastasisCases (%)pN02164 (45.8%)pN1 (1-2)1265 (26.8%)pN2 (3-6)790 (16.7%)pN3 (7-)392 (8.3%)Unknown111 (2.4%)Total4722Regional lymph nodes are different in JES 10th and UICC 7thData for Tables [23](#Tab23){ref-type="table"} and [24](#Tab24){ref-type="table"} were analyzed from different variables in the registration application (Tables [25](#Tab25){ref-type="table"}, [26](#Tab26){ref-type="table"}, [27](#Tab27){ref-type="table"})Table 25Pathological findings of distant organ metastasis, pM (JES 10th)Distant metastasisCases (%)pMX172 (3.6%)pM04490 (95.1%)pM160 (1.3%)Total4722Table 26Residual tumorResidual tumorCases (%)RX156 (3.3%)R04160 (88.1%)R1216 (4.6%)R2190 (4.0%)Total472Table 27Causes of deathCause of deathCases (%)Death due to recurrence1383 (71.5%)Death due to other cancer101 (5.2%) Death due to other disease (with recurrence)46 (2.4%) Death due to other disease (without recurrence)244 (12.6%) Death due to other disease (recurrence unknown)19 (1.0%)Operative death^a^25 (1.3%)Postoperative hospital death^b^40 (2.1%)Unknown77 (4.0%)Total of death cases1935Operative mortality rate: 0.52%Hospital mortality rate: 2.35%^a^Operative death means death within 30 days after operation in or out of hospital^b^Hospital death is defined as death during the same hospitalization, regardless of department at time of death

These data were first made available on March 2019, as the Comprehensive Registry of Esophageal Cancer in Japan, 2012.

The authors were members of the Registration Committee for Esophageal Cancer, the Japan Esophageal Society, and made great contributions to the preparation of this material.

**Publisher\'s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.

Informed consent or substitute for it was obtained from all patients for being included in the study.

All authors have nothing to disclose with regard to commercial support.
